Titre : Mépacrine

Mépacrine : Questions médicales fréquentes

Termes MeSH sélectionnés :

Age Distribution
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Mépacrine : Questions médicales les plus fréquentes", "headline": "Mépacrine : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Mépacrine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-23", "dateModified": "2025-04-18", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Mépacrine" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Aminoacridines", "url": "https://questionsmedicales.fr/mesh/D000609", "about": { "@type": "MedicalCondition", "name": "Aminoacridines", "code": { "@type": "MedicalCode", "code": "D000609", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.300.046.250" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Moutarde de quinacrine", "alternateName": "Quinacrine Mustard", "url": "https://questionsmedicales.fr/mesh/D011797", "about": { "@type": "MedicalCondition", "name": "Moutarde de quinacrine", "code": { "@type": "MedicalCode", "code": "D011797", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.300.046.250.760.750" } } } ], "about": { "@type": "MedicalCondition", "name": "Mépacrine", "alternateName": "Quinacrine", "code": { "@type": "MedicalCode", "code": "D011796", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Chanakya Nath Kundu", "url": "https://questionsmedicales.fr/author/Chanakya%20Nath%20Kundu", "affiliation": { "@type": "Organization", "name": "Cancer Biology Division, School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Deemed to be University, Campus-11, Patia, Bhubaneswar, Odisha, 751024, India. cnkundu@kiitbiotech.ac.in." } }, { "@type": "Person", "name": "Thomas R Lane", "url": "https://questionsmedicales.fr/author/Thomas%20R%20Lane", "affiliation": { "@type": "Organization", "name": "Collaborations Pharmaceuticals, Inc., Raleigh, North Carolina, USA." } }, { "@type": "Person", "name": "Sean Ekins", "url": "https://questionsmedicales.fr/author/Sean%20Ekins", "affiliation": { "@type": "Organization", "name": "Collaborations Pharmaceuticals, Inc., Raleigh, North Carolina, USA peter.madrid@sri.com sean@collaborationspharma.com." } }, { "@type": "Person", "name": "Biswajit Das", "url": "https://questionsmedicales.fr/author/Biswajit%20Das", "affiliation": { "@type": "Organization", "name": "Cancer Biology Division, School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Deemed to be University, Campus-11, Patia, Bhubaneswar, Odisha, 751024, India." } }, { "@type": "Person", "name": "Chinmayee Sethy", "url": "https://questionsmedicales.fr/author/Chinmayee%20Sethy", "affiliation": { "@type": "Organization", "name": "Cancer Biology Division, School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Deemed to be University, Campus-11, Patia, Bhubaneswar, Odisha, 751024, India." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Age distribution and prevalence in different age groups of four myositis-specific autoantibodies, including anti-ARS, anti-MDA5, anti-Mi-2, and anti-TIF1γ antibodies.", "datePublished": "2023-03-08", "url": "https://questionsmedicales.fr/article/36890683", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/1346-8138.16772" } }, { "@type": "ScholarlyArticle", "name": "Age distribution of Antarctic Bottom Water off Cape Darnley, East Antarctica, estimated using chlorofluorocarbon and sulfur hexafluoride.", "datePublished": "2022-05-19", "url": "https://questionsmedicales.fr/article/35589760", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-022-12109-4" } }, { "@type": "ScholarlyArticle", "name": "Genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: A systematic review and meta-analysis.", "datePublished": "2022-09-06", "url": "https://questionsmedicales.fr/article/36085257", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.vaccine.2022.07.052" } }, { "@type": "ScholarlyArticle", "name": "Increased incidence of rare cancers and varied age distributions by cancer group: A population-based cancer registry study in Hiroshima Prefecture, Japan.", "datePublished": "2023-02-11", "url": "https://questionsmedicales.fr/article/36780834", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.canep.2023.102336" } }, { "@type": "ScholarlyArticle", "name": "Age distribution and disease severity of COVID-19 patients continued to change in a time-dependent manner from May 2021 to April 2022 in the regional core hospital in Japan.", "datePublished": "2023-02-26", "url": "https://questionsmedicales.fr/article/36843034", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.5582/ddt.2022.01111" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérocycliques 3 noyaux", "item": "https://questionsmedicales.fr/mesh/D006575" }, { "@type": "ListItem", "position": 5, "name": "Acridines", "item": "https://questionsmedicales.fr/mesh/D000166" }, { "@type": "ListItem", "position": 6, "name": "Aminoacridines", "item": "https://questionsmedicales.fr/mesh/D000609" }, { "@type": "ListItem", "position": 7, "name": "Mépacrine", "item": "https://questionsmedicales.fr/mesh/D011796" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Mépacrine - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Mépacrine", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Mépacrine", "description": "Comment diagnostiquer une infection nécessitant la mépacrine ?\nQuels tests sont utilisés pour la mépacrine ?\nLa mépacrine est-elle utilisée pour des maladies spécifiques ?\nQuels symptômes indiquent un besoin de mépacrine ?\nComment évaluer l'efficacité de la mépacrine ?", "url": "https://questionsmedicales.fr/mesh/D011796?mesh_terms=Age+Distribution&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Mépacrine", "description": "Quels sont les effets secondaires courants de la mépacrine ?\nLa mépacrine peut-elle provoquer des réactions allergiques ?\nQuels symptômes indiquent une surdose de mépacrine ?\nLa mépacrine affecte-t-elle le système digestif ?\nQuels signes d'infection nécessitent un traitement par mépacrine ?", "url": "https://questionsmedicales.fr/mesh/D011796?mesh_terms=Age+Distribution&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Mépacrine", "description": "Comment prévenir les infections traitées par mépacrine ?\nLes voyages dans certaines zones augmentent-ils le risque d'infection ?\nDes vaccins existent-ils pour prévenir les infections ?\nComment réduire le risque de piqûres de moustiques ?\nLa mépacrine peut-elle être utilisée en prévention ?", "url": "https://questionsmedicales.fr/mesh/D011796?mesh_terms=Age+Distribution&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Mépacrine", "description": "Comment la mépacrine est-elle administrée ?\nQuelle est la posologie standard de mépacrine ?\nLa mépacrine est-elle efficace contre tous les parasites ?\nPeut-on combiner la mépacrine avec d'autres traitements ?\nQuels sont les traitements alternatifs à la mépacrine ?", "url": "https://questionsmedicales.fr/mesh/D011796?mesh_terms=Age+Distribution&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Mépacrine", "description": "Quelles complications peuvent survenir avec la mépacrine ?\nLa mépacrine peut-elle causer des problèmes hématologiques ?\nQuels signes indiquent une complication grave ?\nComment gérer les complications liées à la mépacrine ?\nLes complications sont-elles fréquentes avec la mépacrine ?", "url": "https://questionsmedicales.fr/mesh/D011796?mesh_terms=Age+Distribution&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Mépacrine", "description": "Quels facteurs augmentent le risque d'infection ?\nL'âge influence-t-il le risque d'effets secondaires ?\nLes antécédents médicaux jouent-ils un rôle ?\nLe sexe influence-t-il la réponse à la mépacrine ?\nLes interactions médicamenteuses sont-elles un risque ?", "url": "https://questionsmedicales.fr/mesh/D011796?mesh_terms=Age+Distribution&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une infection nécessitant la mépacrine ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests de laboratoire pour identifier les parasites." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour la mépacrine ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des analyses de selles peuvent être effectués." } }, { "@type": "Question", "name": "La mépacrine est-elle utilisée pour des maladies spécifiques ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle est utilisée pour traiter la leishmaniose et certaines maladies auto-immunes." } }, { "@type": "Question", "name": "Quels symptômes indiquent un besoin de mépacrine ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la fièvre, des douleurs abdominales et des éruptions cutanées peuvent indiquer une infection." } }, { "@type": "Question", "name": "Comment évaluer l'efficacité de la mépacrine ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité est évaluée par la réduction des symptômes et des résultats de tests de suivi." } }, { "@type": "Question", "name": "Quels sont les effets secondaires courants de la mépacrine ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent des nausées, des vomissements et des éruptions cutanées." } }, { "@type": "Question", "name": "La mépacrine peut-elle provoquer des réactions allergiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des réactions allergiques comme des démangeaisons ou un gonflement peuvent survenir." } }, { "@type": "Question", "name": "Quels symptômes indiquent une surdose de mépacrine ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes de surdose incluent des vertiges, des troubles de la vision et des convulsions." } }, { "@type": "Question", "name": "La mépacrine affecte-t-elle le système digestif ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut causer des troubles digestifs comme des douleurs abdominales et des diarrhées." } }, { "@type": "Question", "name": "Quels signes d'infection nécessitent un traitement par mépacrine ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des douleurs abdominales sévères et de la fièvre persistante peuvent nécessiter un traitement." } }, { "@type": "Question", "name": "Comment prévenir les infections traitées par mépacrine ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention inclut des mesures d'hygiène, l'utilisation de moustiquaires et des vaccins." } }, { "@type": "Question", "name": "Les voyages dans certaines zones augmentent-ils le risque d'infection ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, voyager dans des zones endémiques augmente le risque d'infections parasitaires." } }, { "@type": "Question", "name": "Des vaccins existent-ils pour prévenir les infections ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des vaccins sont disponibles pour certaines infections, mais pas pour toutes." } }, { "@type": "Question", "name": "Comment réduire le risque de piqûres de moustiques ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser des répulsifs, porter des vêtements longs et installer des moustiquaires." } }, { "@type": "Question", "name": "La mépacrine peut-elle être utilisée en prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Elle n'est généralement pas utilisée en prévention, mais plutôt en traitement actif." } }, { "@type": "Question", "name": "Comment la mépacrine est-elle administrée ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "La mépacrine est généralement administrée par voie orale sous forme de comprimés." } }, { "@type": "Question", "name": "Quelle est la posologie standard de mépacrine ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La posologie varie selon l'infection, mais elle est souvent de 100 à 200 mg par jour." } }, { "@type": "Question", "name": "La mépacrine est-elle efficace contre tous les parasites ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Non, elle est principalement efficace contre certains parasites comme ceux de la leishmaniose." } }, { "@type": "Question", "name": "Peut-on combiner la mépacrine avec d'autres traitements ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut être combinée avec d'autres médicaments selon la maladie traitée." } }, { "@type": "Question", "name": "Quels sont les traitements alternatifs à la mépacrine ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des alternatives incluent l'antimoniate de méglumine et d'autres antiparasitaires." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec la mépacrine ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des troubles hépatiques et des réactions cutanées sévères." } }, { "@type": "Question", "name": "La mépacrine peut-elle causer des problèmes hématologiques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut entraîner des troubles sanguins comme l'anémie ou la thrombocytopénie." } }, { "@type": "Question", "name": "Quels signes indiquent une complication grave ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des saignements inhabituels ou des douleurs abdominales sévères doivent alerter." } }, { "@type": "Question", "name": "Comment gérer les complications liées à la mépacrine ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "La gestion inclut l'arrêt du médicament et un suivi médical approprié." } }, { "@type": "Question", "name": "Les complications sont-elles fréquentes avec la mépacrine ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les complications sont rares mais peuvent survenir, nécessitant une surveillance." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque d'infection ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent un système immunitaire affaibli, des voyages dans des zones à risque." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque d'effets secondaires ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées peuvent être plus sensibles aux effets secondaires de la mépacrine." } }, { "@type": "Question", "name": "Les antécédents médicaux jouent-ils un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de maladies hépatiques ou sanguines augmentent le risque." } }, { "@type": "Question", "name": "Le sexe influence-t-il la réponse à la mépacrine ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Des études montrent que le sexe peut influencer la pharmacocinétique de la mépacrine." } }, { "@type": "Question", "name": "Les interactions médicamenteuses sont-elles un risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines interactions peuvent augmenter les effets secondaires ou réduire l'efficacité." } } ] } ] }

Sources (10000 au total)

Genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: A systematic review and meta-analysis.

National HPV vaccination coverage in Japan is less than one percent of the eligible population and cervical cancer incidence and mortality are increasing. This systematic review and meta-analysis aime... English and Japanese databases were searched to March 2021 for research reporting HPV genotypes in cytology and histology samples from Japanese women. Summary estimates were calculated by disease stag... A total of 57759 women with normal cytology, 1766 ASCUS, 3764 LSIL, 2017 HSIL, 3130 CIN1, 1219 CIN2, 869 CIN3/AIS, and 4306 ICC (which included 1032 ICC-SCC, and 638 ICC-ADC) were tested for HPV. The ... HPV prevalence is high among Japanese women. The nonavalent vaccine is likely to have the greatest impact on reducing cervical cancer incidence and mortality in Japan....

Increased incidence of rare cancers and varied age distributions by cancer group: A population-based cancer registry study in Hiroshima Prefecture, Japan.

Epidemiological characteristics of many types of rare cancers are limited especially in Asia. Therefore, this study aimed to describe the burden and changing time trends of rare cancers in Hiroshima, ... The internationally agreed RARECAREnet list of rare cancers was used to identify patients diagnosed with cancers from 2005 to 2015 who were registered in the Hiroshima Prefecture Cancer Registry. Qual... The 231,328 cases were used to calculate the IRs of each cancer. Epithelial tumors in rare families increased with age, but nonepithelial tumors occurred at any age. The proportion of rare cancer fami... The ASRs of several rare cancers increased because of increased knowledge of these diseases, improved diagnostic techniques, and aggressive diagnoses....

Age distribution and disease severity of COVID-19 patients continued to change in a time-dependent manner from May 2021 to April 2022 in the regional core hospital in Japan.

The present retrospective study aimed to examine the real-world data regarding time-dependent changes in the age distribution of patients with coronavirus disease 2019 (COVID-19) as well as the severi...

Global trends, regional differences and age distribution for the incidence of HIV and tuberculosis co-infection from 1990 to 2019: results from the global burden of disease study 2019.

People living with human immunodeficiency virus (HIV) are more likely to develop tuberculosis (TB), and their co-infection (HIV-TB) increases the risk of death. We aimed to describe the global trends,... Annual new cases, age-standardized incidence rates (ASRs) and age-specific incidence rates with 95% uncertainty intervals (UIs) of HIV-infected drug-susceptible tuberculosis (HIV-DS-TB), HIV-infected ... The ASR of HIV-XDR-TB increased significantly by an average of 14.77% (95% CI: 11.05%-18.62%) per year during 1990-2019 worldwide, while the ASRs of HIV-DS-TB and HIV-MDR-TB decreased after 2005. HIV-... HIV-infected drug-resistant TB is common in Oceania and Eastern Europe. Moreover, HIV-XDR-TB among elderly people became increasingly prevalent. In the future, the collaboration of management for HIV ...

Impact of subgroup-specific heterogeneities and dynamic changes in mortality rates on forecasted population size, deaths, and age distribution of persons receiving antiretroviral treatment in the United States: a computer simulation study.

Model-based forecasts of population size, deaths, and age distribution of people with HIV (PWH) are helpful for public health and clinical services planning but are influenced by subgroup-specific het... Using an agent-based simulation of PWH in the United States, we examined the impact of distinct approaches to parametrizing mortality rates on forecasted epidemiology of PWH on antiretroviral treatmen... Among the eight scenarios examined, those lacking subgroup-specific heterogeneities and those allowing unrestricted reductions in future mortality rates forecasted the lowest number of deaths among al... Our results underscore the potential risk of underestimating future deaths by models lacking subgroup-specific heterogeneities in mortality rates, and those allowing unrestricted reductions in future ...

Incidence and distribution of ocular disorders in the first year of life.

To describe the incidence and distribution of eye diseases affecting children in the first year of life in Olmsted County, Minnesota.... We conducted a population-based, retrospective medical record review of infants (≤1 year of age) residing in Olmsted County diagnosed with an ocular disorder from January 1, 2005, through December 31,... A total of 4,223 infants were diagnosed with an ocular disorder, yielding an incidence of 20,242/100,000 births per year, or 1 in 4.9 live births (95% CI, 19,632-20,853). The median age at diagnosis w... Although ocular disorders occurred in 1 in 5 infants in this cohort, most conditions were evaluated and managed by primary care providers. Understanding the incidence and distribution of ocular diseas...

Using electronic medical record data to establish and monitor the distribution of refractive errors

To establish the baseline distribution of refractive errors and associated factors amongst a population that attended primary care optometry clinics.... Retrospective cross sectional cohort study of electronic medical records (EMR).... Electronic medical record data was extracted from forty optometry clinics, representing a mix of urban and rural areas in Ireland. The analysis was confined to demographic and clinical data gathered o... 153,598 clinic records were eligible for analysis. Refractive errors ranged from -26.00 to +18.50 D. Myopia was present in 32.7%, of which high myopia represented 2.4%, hyperopia in 40.1%, astigmatism... Although EMR data is not representative of the population as a whole, it is likely to provide a reasonable representation of the distribution of clinically significant (symptomatic) refractive errors....